Freeline to Present Data at the 2021 Virtual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD) and the 17th Annual WORLDSymposium™ 2021
LONDON, Jan. 26, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage, fully integrated, next generation, systemic AAV-based gene therapy company with the ambition of transforming the lives of patients suffering from inherited systemic debilitating diseases, today announced that it will present two e-posters at the 2021 Virtual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD) taking place 3-5 February 2021. In addition, the Company will present data on its gene therapy programmes for Gaucher and Fabry Disease, in one oral platform presentation and three e-posters at the 17TH Annual WORLDSymposium™ taking place 8-12 February 2021.
EAHAD Presentation Details
| Title: | Follow-up on a Novel Adeno Associated Virus (AAV) Gene Therapy (FLT180a) Achieving Normal FIX Activity Levels in Severe Hemophilia B (HB) Patients (B-AMAZE Study) | |
| Presenter: | Pratima Chowdary, Katharine Dormandy Haemophilia and Thrombosis Centre, Royal Free Hospital, University College London | |
| Presentation #: | ABS-114 | |
| Date and Time: | Tuesday, 2 February 2021, 6:00 CET |
| Title: | Insight into the Persistent Clinical Burden Underlying Problem Joints, Pain, and Bleeding in Adults from Across Europe with Haemophilia A and B: The CHESS II Study | |
| Presenter: | Sharmila Kar, Head of Real-World Evidence, Freeline | |
| Presentation #: | ABS-134 | |
| Date: | Tuesday, 2 February 2021, 6:00 CET | |
| The e-poster presentations will be available from Tuesday, 2 February 2021, as recordings on the section of the Freeline website. | ||
WORLDSymposium™ Presentation Details
Platform presentation:
| Title: | FLT201: An AAV-Mediated Gene Therapy for Type 1 Gaucher Disease Designed to Target Difficult to Reach Tissues | |
| Author: | Romuald Corbau, Chief Scientific Officer, Freeline | |
| Date and Time: | Thursday, 11 February 2021, 11:36am EST |
Poster presentations:
| Title: | FLT201: An AAV-Mediated Gene Therapy for Type 1 Gaucher Disease Designed to Target Difficult to Reach Tissues | |
| Author: | Romuald Corbau, Chief Scientific Officer, Freeline | |
| Presentation #: | 44 | |
| Date: | Thursday, 11 February 2021 |
| Title: | Generation of β-Glucocerebrosidase Variants with Increased Half-Life in Human Plasma for Liver Directed AAV Gene Therapy Aimed at the Treatment of Type 1 Gaucher Disease | |
| Author: | Fabrizio Comper, Scientific Director, Freeline | |
| Presentation #: | 41 | |
| Date: | Thursday, 11 February 2021 |
| Title: | Development of a GLA nAb Assay with a Fully-Human, Neutralizing IgG4 Positive Control to Characterize Antibody Response in Fabry Disease Patients | |
| Author: | Sujata Ravi, Scientist, Freeline | |
| Presentation #: | 211 | |
| Date: | Thursday, 11 February 2021 |
The poster presentations will be available on the section of the Freeline website from 2:30 pm EST on Monday, 8 February 2021. A recording of the platform presentation with a live Q&A will be available after the presentation concludes on Thursday, 11 February 2021, also on the section of the Freeline website.
About Freeline
Freeline is a clinical-stage biotechnology company focused on AAV-based gene therapy targeting the liver. Its vision is to create better lives for people suffering from chronic, systemic diseases using the potential of gene therapy as a one-time treatment to provide a potential functional cure. Freeline is headquartered in the UK and has operations in Germany and the US.
Forward-Looking Statements
This press release contains statements that constitute “forward-looking statements” as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements that express the Company’s opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results, in contrast with statements that reflect historical facts. Examples include discussion of the Company’s strategies, financing plans, research, pipeline and clinical trial plans. In some cases, you can identify such forward-looking statements by terminology such as “anticipate,” “intend,” “believe,” “estimate,” “plan,” “seek,” “project” or “expect,” “may,” “will,” “would,” “could” or “should,” the negative of these terms or similar expressions. Forward looking statements are based on management’s current beliefs and assumptions and on information currently available to the Company, and you should not place undue reliance on such statements. Forward-looking statements are subject to many risks and uncertainties, including the Company’s recurring losses from operations; the development of the Company’s product candidates, including statements regarding the timing of initiation, completion and the outcome of clinical studies or trials and related preparatory work; the Company’s ability to design and implement successful clinical trials for its product candidates; the potential for a pandemic, epidemic or outbreak of infectious diseases in the U.S., U.K. or EU, including the COVID-19 pandemic, to disrupt the Company’s clinical trial pipeline; the Company’s failure to demonstrate the safety and efficacy of its product candidates; the fact that results obtained in earlier stage clinical testing may not be indicative of results in future clinical trials; the Company’s ability to enroll patients in clinical trials for its product candidates; the possibility that one or more of the Company’s product candidates may cause serious adverse, undesirable or unacceptable side effects or have other properties that could delay or prevent their regulatory approval or limit their commercial potential; the Company’s ability to obtain and maintain regulatory approval of its product candidates; the Company’s limited manufacturing experience which could result in delays in the development or commercialization of its product candidates; and the Company’s ability to identify or discover additional product candidates, or failure to capitalize on programs or product candidates. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of these risks are outside of the Company’s control and could cause its actual results to differ materially from those it thought would occur. The forward-looking statements included in this press release are made only as of the date hereof. The Company does not undertake, and specifically declines, any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments, except as required by law.
For further information, please reference the Company’s reports and documents filed with the U.S. Securities and Exchange Commission. You may get these documents by visiting EDGAR on the SEC website at .
Further Information
David S. Arrington
VP Investor Relations & Corporate Communications
+1 (646) 668 6947
United States
LifeSci Advisors
Dan Ferry
+1 (617) 430 7576
Europe
JW Communications
Julia Wilson
+44 (0) 7818 430877
